vs
Emergent BioSolutions Inc.（EBS）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
BRC Group Holdings, Inc.の直近四半期売上が大きい（$188.3M vs $148.7M、Emergent BioSolutions Inc.の約1.3倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs -36.7%、差は84.7%）。BRC Group Holdings, Inc.の前年同期比売上増加率が高い（-21.9% vs -23.6%）。過去8四半期でBRC Group Holdings, Inc.の売上複合成長率が高い（-15.4% vs -29.6%）
Emergent BioSolutionsはアメリカ合衆国メリーランド州ゲイザーズバーグに本社を置く多国籍専門生物製薬企業です。感染症やオピオイド過剰摂取に対応するワクチンと抗体治療薬の開発を主力事業とし、生物防衛分野向けの医療機器も提供しています。
EBS vs RILY — 直接比較
売上が大きい
RILY
1.3倍大きい
$148.7M
売上成長率が高い
RILY
+1.8%の差
-23.6%
純利益率が高い
RILY
純利益率が84.7%高い
-36.7%
2年売上CAGRが高い
RILY
2年複合成長率
-29.6%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $148.7M | $188.3M |
| 純利益 | $-54.6M | $90.3M |
| 粗利率 | 42.9% | 79.5% |
| 営業利益率 | -18.8% | 32.3% |
| 純利益率 | -36.7% | 47.9% |
| 売上前年比 | -23.6% | -21.9% |
| 純利益前年比 | -74.4% | 1710.8% |
| EPS（希薄化後） | $-0.95 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上EBSRILY
| Q4 25 | $148.7M | $188.3M | ||
| Q3 25 | $231.1M | $215.3M | ||
| Q2 25 | $140.9M | $188.2M | ||
| Q1 25 | $222.2M | $197.2M | ||
| Q4 24 | $194.7M | $241.0M | ||
| Q3 24 | $293.8M | $225.5M | ||
| Q2 24 | $254.7M | $256.0M | ||
| Q1 24 | $300.4M | $263.4M |
純利益EBSRILY
| Q4 25 | $-54.6M | $90.3M | ||
| Q3 25 | $51.2M | $91.1M | ||
| Q2 25 | $-12.0M | $139.5M | ||
| Q1 25 | $68.0M | $-10.0M | ||
| Q4 24 | $-31.3M | $-5.6M | ||
| Q3 24 | $114.8M | $-284.4M | ||
| Q2 24 | $-283.1M | $-433.6M | ||
| Q1 24 | $9.0M | $-49.2M |
粗利率EBSRILY
| Q4 25 | 42.9% | 79.5% | ||
| Q3 25 | 62.8% | 83.7% | ||
| Q2 25 | 52.5% | 81.3% | ||
| Q1 25 | 60.2% | 81.4% | ||
| Q4 24 | 39.4% | 79.8% | ||
| Q3 24 | 54.9% | 82.1% | ||
| Q2 24 | -18.8% | 84.5% | ||
| Q1 24 | 49.2% | 85.3% |
営業利益率EBSRILY
| Q4 25 | -18.8% | 32.3% | ||
| Q3 25 | 33.1% | 30.4% | ||
| Q2 25 | 1.1% | 5.7% | ||
| Q1 25 | 22.5% | -31.2% | ||
| Q4 24 | -4.9% | -69.2% | ||
| Q3 24 | 22.0% | -36.4% | ||
| Q2 24 | -79.9% | -90.8% | ||
| Q1 24 | 13.2% | -6.1% |
純利益率EBSRILY
| Q4 25 | -36.7% | 47.9% | ||
| Q3 25 | 22.2% | 42.3% | ||
| Q2 25 | -8.5% | 74.1% | ||
| Q1 25 | 30.6% | -5.1% | ||
| Q4 24 | -16.1% | -2.3% | ||
| Q3 24 | 39.1% | -126.1% | ||
| Q2 24 | -111.2% | -169.4% | ||
| Q1 24 | 3.0% | -18.7% |
EPS（希薄化後）EBSRILY
| Q4 25 | $-0.95 | $2.78 | ||
| Q3 25 | $0.91 | $2.91 | ||
| Q2 25 | $-0.22 | $4.50 | ||
| Q1 25 | $1.19 | $-0.39 | ||
| Q4 24 | $-0.45 | $-0.01 | ||
| Q3 24 | $2.06 | $-9.39 | ||
| Q2 24 | $-5.38 | $-14.35 | ||
| Q1 24 | $0.17 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $205.4M | $226.6M |
| 総負債低いほど良い | $589.7M | $1.4B |
| 株主資本純資産 | $522.6M | $-171.5M |
| 総資産 | $1.3B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 1.13× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資EBSRILY
| Q4 25 | $205.4M | $226.6M | ||
| Q3 25 | $245.5M | $184.2M | ||
| Q2 25 | $267.3M | $267.4M | ||
| Q1 25 | $149.1M | $138.3M | ||
| Q4 24 | $99.5M | $146.9M | ||
| Q3 24 | $149.9M | $159.2M | ||
| Q2 24 | $69.7M | $236.9M | ||
| Q1 24 | $78.5M | $190.7M |
総負債EBSRILY
| Q4 25 | $589.7M | $1.4B | ||
| Q3 25 | $693.1M | $1.3B | ||
| Q2 25 | $700.0M | $1.3B | ||
| Q1 25 | $700.0M | $1.4B | ||
| Q4 24 | $700.0M | $1.5B | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
株主資本EBSRILY
| Q4 25 | $522.6M | $-171.5M | ||
| Q3 25 | $582.5M | $-260.5M | ||
| Q2 25 | $536.2M | $-351.7M | ||
| Q1 25 | $552.7M | $-496.8M | ||
| Q4 24 | $482.8M | $-488.2M | ||
| Q3 24 | $508.4M | $-497.6M | ||
| Q2 24 | $386.3M | $-218.3M | ||
| Q1 24 | $663.9M | $228.4M |
総資産EBSRILY
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.5B | $1.7B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.5B | $3.2B | ||
| Q1 24 | $1.8B | $5.0B |
負債/資本比率EBSRILY
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $77.7M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $73.8M | — |
| FCFマージンFCF / 売上 | 49.6% | — |
| 設備投資強度設備投資 / 売上 | 2.6% | — |
| キャッシュ転換率営業CF / 純利益 | — | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $156.8M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローEBSRILY
| Q4 25 | $77.7M | $26.2M | ||
| Q3 25 | $-2.3M | $-60.6M | ||
| Q2 25 | $106.4M | $-25.6M | ||
| Q1 25 | $-11.2M | $184.0K | ||
| Q4 24 | $-79.9M | $-2.7M | ||
| Q3 24 | $153.7M | $19.5M | ||
| Q2 24 | $47.5M | $111.5M | ||
| Q1 24 | $-62.6M | $135.4M |
フリーキャッシュフローEBSRILY
| Q4 25 | $73.8M | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $103.5M | — | ||
| Q1 25 | $-14.8M | — | ||
| Q4 24 | $-81.6M | — | ||
| Q3 24 | $147.9M | — | ||
| Q2 24 | $42.9M | — | ||
| Q1 24 | $-73.4M | — |
FCFマージンEBSRILY
| Q4 25 | 49.6% | — | ||
| Q3 25 | -2.5% | — | ||
| Q2 25 | 73.5% | — | ||
| Q1 25 | -6.7% | — | ||
| Q4 24 | -41.9% | — | ||
| Q3 24 | 50.3% | — | ||
| Q2 24 | 16.8% | — | ||
| Q1 24 | -24.4% | — |
設備投資強度EBSRILY
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 3.6% | — |
キャッシュ転換率EBSRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | -0.04× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.96× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
